LENZ Therapeutics Statistics
Total Valuation
LENZ has a market cap or net worth of $822.71 million. The enterprise value is $587.80 million.
Important Dates
The next confirmed earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LENZ has 27.54 million shares outstanding. The number of shares has increased by 986.27% in one year.
| Current Share Class | 27.54M |
| Shares Outstanding | 27.54M |
| Shares Change (YoY) | +986.27% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 2.82% |
| Owned by Institutions (%) | 42.83% |
| Float | 11.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 20.89 |
| PB Ratio | 3.89 |
| P/TBV Ratio | 3.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.36, with a Debt / Equity ratio of 0.01.
| Current Ratio | 20.36 |
| Quick Ratio | 20.09 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -38.94% and return on invested capital (ROIC) is -28.47%.
| Return on Equity (ROE) | -38.94% |
| Return on Assets (ROA) | -25.64% |
| Return on Invested Capital (ROIC) | -28.47% |
| Return on Capital Employed (ROCE) | -28.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LENZ has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +88.93% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +88.93% |
| 50-Day Moving Average | 24.18 |
| 200-Day Moving Average | 25.99 |
| Relative Strength Index (RSI) | 65.39 |
| Average Volume (20 Days) | 308,222 |
Short Selling Information
The latest short interest is 2.89 million, so 10.51% of the outstanding shares have been sold short.
| Short Interest | 2.89M |
| Short Previous Month | 2.51M |
| Short % of Shares Out | 10.51% |
| Short % of Float | 25.81% |
| Short Ratio (days to cover) | 9.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -58.61M |
| Pretax Income | -117.37M |
| Net Income | -49.77M |
| EBITDA | -58.55M |
| EBIT | -58.61M |
| Earnings Per Share (EPS) | -$2.34 |
Full Income StatementBalance Sheet
The company has $209.03 million in cash and $1.38 million in debt, giving a net cash position of $207.65 million or $7.54 per share.
| Cash & Cash Equivalents | 209.03M |
| Total Debt | 1.38M |
| Net Cash | 207.65M |
| Net Cash Per Share | $7.54 |
| Equity (Book Value) | 204.08M |
| Book Value Per Share | 7.42 |
| Working Capital | 201.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$59.39 million and capital expenditures -$468,000, giving a free cash flow of -$59.86 million.
| Operating Cash Flow | -59.39M |
| Capital Expenditures | -468,000 |
| Free Cash Flow | -59.86M |
| FCF Per Share | -$2.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |